Literature DB >> 19760638

Radical prostatectomy: influence on serum and urinary androgen levels.

Mats Olsson1, Lena Ekström, Jenny Schulze, Anders Kjellman, Olof Akre, Anders Rane, Ove Gustafsson.   

Abstract

BACKGROUND: The role of the prostate as an active endocrine organ and the hormonal changes after radical prostatectomy (RP) has not been well studied. The objective of this study was to investigate the serum and urine hormonal changes after RP.
METHODS: Fifty-five healthy men with localized prostate cancer were enrolled in this cross-sectional study at a single academic center. We measured serum levels of testosterone, dihydrotestosterone (DHT), sex hormone binding globulin (SHBG), luteinizing hormone (LH), and follicle stimulating hormone (FSH) in all 55 patients preoperatively and in 53 patients 90 days postoperatively. Free testosterone was calculated in all patients. Inhibin B levels was analyzed in 44 patients pre- and postoperatively. Steroid urine profile including testosterone, DHT, 5alpha-androstane-3alpha,17beta-diol (3alphaAdiol), and androsterone (ADT) was also determined preoperatively and 90 days postoperatively in 18 patients.
RESULTS: There were 53% increase in serum LH (P < 0.0001), 21% increase in serum FSH (P < 0.0001), and 13% decrease in DHT levels (P < 0.03). There were no significant changes in any other serum hormone investigated. Urinary levels of DHT glucuronides (DHT-G) decreased by 67% (P < 0.0003) while Androsterone-G and 3alphaAdiol-G increased by 37% (P = 0.019) and 44% (P = 0.023), respectively. There were no alterations in the urinary levels of the other steroids investigated. Inhibin B levels correlated inversely with both FSH (r = -0.67, P < 0.0001) and LH (r = -0.51, P = 0.0004).
CONCLUSION: RP leads to significant increases in serum gonadotropins and significant DHT decrease in both serum and urine. These hormonal changes are independent of inhibin B.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19760638     DOI: 10.1002/pros.21053

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  7 in total

1.  Preoperative Plasma Levels of Total Testosterone Associated with High Grade Pathology-Detected Prostate Cancer: Preliminary Results of a Prospective Study in a Contemporary Cohort of Patients.

Authors:  Antonio B Porcaro; Nicolò De Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Giovanni Cacciamani; Davide De Marchi; Irene Tamanini; Davide Inverardi; Matteo Brunelli; Maria A Cerruto; Gian L Salvagno; Gian C Guidi; Walter Artibani
Journal:  Curr Urol       Date:  2017-05-30

2.  Simultaneous Measurements of Follicle Stimulating Hormone and Total Testosterone and Associations in Clinically Localized Prostate Cancer.

Authors:  Antonio B Porcaro; Salvatore Siracusano; Nicolò de Luyk; Paolo Corsi; Marco Sebben; Alessandro Tafuri; Tania Processali; Davide Inverardi; Giovanni Cacciamani; Daniele Mattevi; Maria A Cerruto; Matteo Brunelli; Claudio Ghimenton; Carmelo Monaco; Walter Artibani
Journal:  Curr Urol       Date:  2017-10-22

3.  Changes in sex hormone levels after radical prostatectomy: Results of a longitudinal cohort study.

Authors:  Mauro Gacci; Nicola Tosi; Gianni Vittori; Andrea Minervini; Giovanni Corona; Tommaso Cai; Anna Maria Morelli; Linda Vignozzi; Sergio Serni; Mario Maggi; Marco Carini
Journal:  Oncol Lett       Date:  2013-06-21       Impact factor: 2.967

Review 4.  Quality of Life and Sexual Health in the Aging of PCa Survivors.

Authors:  Mauro Gacci; Elisabetta Baldi; Lara Tamburrino; Beatrice Detti; Lorenzo Livi; Cosimo De Nunzio; Andrea Tubaro; Stavros Gravas; Marco Carini; Sergio Serni
Journal:  Int J Endocrinol       Date:  2014-03-17       Impact factor: 3.257

Review 5.  Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapists.

Authors:  Giovanni L Gravina; Stefania Di Sante; Erika Limoncin; Daniele Mollaioli; Giacomo Ciocca; Eleonora Carosa; Patrizia Sanità; Ernesto Di Cesare; Andrea Lenzi; Emmanuele A Jannini
Journal:  Transl Androl Urol       Date:  2015-04

6.  Prostate cancer volume associates with preoperative plasma levels of testosterone that independently predicts high grade tumours which show low densities (quotient testosterone/tumour volume).

Authors:  Antonio B Porcaro; Aldo Petrozziello; Matteo Brunelli; Filippo Migliorini; Giovanni Cacciamani; Davide De Marchi; Nicolo' de Luyk; Irene Tamanini; Beatrice Caruso; Maria A Cerruto; Claudio Ghimenton; Walter Artibani
Journal:  Asian J Urol       Date:  2015-11-30

7.  Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer.

Authors:  Suguru Tokiwa; Hiroaki Shimmura; Shuhei Nomura; Ryota Watanabe; Minoru Kurita; Naoto Yoshida; Kaori Yamashita; Yoshitaka Nishikawa; Alexander Kouzmenko; Shigeaki Kato
Journal:  Res Rep Urol       Date:  2017-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.